nodal follicular helper T cell lymphoma
Conditions
Interventions
Therapeutic Group:Entinostat + azacitidine +CHOP for nodal follicular helper T-cell lymphoma
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Patients with confirmed nTFHL; 2. no previous chemotherapy, radiotherapy, or other treatments; 3. Aged from 18 to 80 years; 4.ECOG score 0-2; 5. Predicted survival >=3 months; 6. Normal major organ function with laboratory findings meeting the following criteria: (1) alanine aminotransferase (ALT)<=3.0× upper limit of normal value (ULN), aspartate aminotransferase (AST)<=3.0×ULN; (2) Serum total bilirubin <=1.5×ULN; (3) Serum creatinine <=1.5×ULN; 7. Voluntarily participate in the clinical trial, understand the study procedures, and be able to sign in-person informed consent;
Exclusion criteria
Exclusion criteria: 1.Failure to meet the inclusion criteria; 2.women who are pregnant or breastfeeding; 3.Allergy to study drugs and associated metabolites; 4.Active infections difficult to control; 5.Concomitant diseases that, in the judgment of the investigator, seriously endanger patient safety or prevent patients from completing the study; 6.Other conditions judged by the investigator to be unsuitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| complete remission;overall response rate;overall survival;duration of response;disease-free survival;event-free survival; | — |
Countries
China
Contacts
Public ContactXin Wang
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed